These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 9814686)
21. [Antibodies to beta2-glycoprotein-1 in patients with systemic lupus erythematosus]. Borodin AG; Baranov NG; Nasonov EL Klin Med (Mosk); 2001; 79(2):49-51. PubMed ID: 11419087 [TBL] [Abstract][Full Text] [Related]
22. Antibodies to beta2-glycoprotein I: a potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus. Sanfilippo SS; Khamashta MA; Atsumi T; Amengual O; Bertolaccini ML; D'Cruz D; Amft N; Swana GT; Hughes GR J Rheumatol; 1998 Nov; 25(11):2131-4. PubMed ID: 9818654 [TBL] [Abstract][Full Text] [Related]
23. Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Cucurull E; Espinoza LR; Mendez E; Molina JF; Molina J; Ordi-Ros J; Gharavi AE Lupus; 1999; 8(2):134-41. PubMed ID: 10192508 [TBL] [Abstract][Full Text] [Related]
24. Beta2-glycoprotein I: target antigen for 'antiphospholipid' antibodies. Immunological and molecular aspects. Sheng Y; Kandiah DA; Krilis SA Lupus; 1998; 7 Suppl 2():S5-9. PubMed ID: 9814663 [TBL] [Abstract][Full Text] [Related]
25. Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association? Sahin M; Duzgun N; Tunc SE; Tutkak H Clin Rheumatol; 2007 Feb; 26(2):154-60. PubMed ID: 16598413 [TBL] [Abstract][Full Text] [Related]
26. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E Lupus; 2007; 16(1):39-45. PubMed ID: 17283584 [TBL] [Abstract][Full Text] [Related]
27. [Antibodies to beta2-glycoprotein I in systemic lupus erythematosus: new laboratory marker of antiphospholipid syndrome]. Reshetniak TM; Derksen RV; Alekberova ZS; Horbach D; De Groot F; Nasonov EL; Kalashnikova LA; Match ES; Nasonova VA Klin Med (Mosk); 1998; 76(3):36-40. PubMed ID: 9575746 [TBL] [Abstract][Full Text] [Related]
28. IgM, but not IgA rheumatoid factor interferes with anti-cardiolipin and antiβ2 glycoprotein I measurements: a quantitative analysis. Lakos G; Teodorescu M Lupus; 2011 May; 20(6):614-9. PubMed ID: 21436214 [TBL] [Abstract][Full Text] [Related]
29. Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome. Cousins L; Pericleous C; Khamashta M; Bertolaccini ML; Ioannou Y; Giles I; Rahman A Ann Rheum Dis; 2015 Jan; 74(1):317-9. PubMed ID: 25359383 [No Abstract] [Full Text] [Related]
30. Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Zhu M; Olee T; Le DT; Roubey RA; Hahn BH; Woods VL; Chen PP Br J Haematol; 1999 Apr; 105(1):102-9. PubMed ID: 10233371 [TBL] [Abstract][Full Text] [Related]
32. IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. Mattia E; Ruffatti A; Tonello M; Meneghel L; Robecchi B; Pittoni M; Gallo N; Salvan E; Teghil V; Punzi L; Plebani M Clin Chem Lab Med; 2014 Sep; 52(9):1329-33. PubMed ID: 24651022 [TBL] [Abstract][Full Text] [Related]
33. Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome? Galli M Haemostasis; 2000; 30 Suppl 2():57-62. PubMed ID: 11251342 [TBL] [Abstract][Full Text] [Related]
34. [Antiphospholipid antibodies: clinical significance and biological diagnosis]. Arnoux D; Boutière B; Sanmarco M Ann Biol Clin (Paris); 2000; 58(5):557-74. PubMed ID: 11022099 [TBL] [Abstract][Full Text] [Related]
35. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome. Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458 [TBL] [Abstract][Full Text] [Related]
36. Requirement of beta 2 glycoprotein I as cofactor in the binding for IgM and IgA anticardiolipin antibodies. Hanly JG; Hong C; James H; Mansour M; Jones JV J Rheumatol; 1995 Jun; 22(6):1091-6. PubMed ID: 7674235 [TBL] [Abstract][Full Text] [Related]
37. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Guerin J; Casey E; Feighery C; Jackson J Autoimmunity; 1999 Oct; 31(2):109-16. PubMed ID: 10680749 [TBL] [Abstract][Full Text] [Related]
39. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Hunt JE; McNeil HP; Morgan GJ; Crameri RM; Krilis SA Lupus; 1992 Feb; 1(2):75-81. PubMed ID: 1301967 [TBL] [Abstract][Full Text] [Related]
40. Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein 1 (beta2GP1) alone. Gharavi AE; Pierangeli SS; Gharavi EE; Hua T; Liu XW; Barker JH; Anderson GH; Harris EN Lupus; 1998; 7(5):341-6. PubMed ID: 9696138 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]